Article
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
Blood advances - 22 Aug 2023
Pasca Sergiu, Guo Matthew Z, Wang Shiyu, Stokvis Kristin, Shedeck Audra, Pallavajjala Aparna, Shams Cynthia, Pallavajjala Roshni, DeZern Amy E, Varadhan Ravi, Gocke Christopher D, Jones Richard J, Gondek Lukasz P
Abstract excerpt
The measurable residual disease (MRD) assessment provides an attractive predictor of allogeneic hematopoietic cell transplnat (alloHCT) outcomes. Cell-free DNA (cfDNA) has been applied to diagnosis, early detection, and disease burden monitoring in various tumors, but its utility as an MRD test in myeloid malignancies has not been systematically evaluated. We sought to determine the differential sensitivity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.